| GBI Research's pharma report, "Pharmaceutical | | | | Scope |
| Research and Development (R&D) - Increasing | | | | The report analyses the key measures adopted to |
| Efficency Through Information Technology and | | | | improve the R&D efficiency in the |
| Externalization" provides key data, information and | | | | pharmaceutical and biotech industry along with the |
| analysis on major pharmaceutical R&D practices | | | | major challenges that have led to a decrease in the |
| at the global level in order to improve its efficiency | | | | R&D productivity over the last decade. The |
| and effectiveness. This pharmaceutical and healthcare | | | | scope of the report includes: |
| report provides comprehensive insight into the major | | | | - Major challenges in the current pharmaceutical |
| challenges in the current pharmaceutical R&D | | | | R&D landscape. |
| landscape. It analyzes key measures and practices | | | | - Key solutions adopted by the pharmaceutical |
| (mergers and acquisitions, R&D restructuring, | | | | industry to improve the R&D productivity which |
| outsourcing and active lifecycle management) | | | | include strategic mergers and acquisitions, R&D |
| adopted by the pharmaceutical industry to tackle | | | | restructuring, outsourcing and active lifecycle |
| these challenges and improve the R&D | | | | management. |
| efficiency. The report substantiates the analysis with | | | | - More than 25 examples and case studies explaining |
| various case studies to study the effect of measure | | | | each solution and its impact on the R&D |
| post-implementation. The report also provides an | | | | productivity in a short and long term. |
| analytical insight into the potential solutions that have | | | | - Qualitative analysis of the major potential solutions |
| tremendous potential to improve the future | | | | that can improve the R&D productivity in the |
| pharmaceutical and biotech R&D productivity. | | | | future. |
| The pharmaceutical industry has witnessed a | | | | Reasons to buy |
| significant decline in R&D productivity over the | | | | The report will enhance your decision making. It will |
| past few years, which has become a matter of | | | | allow you to: |
| concern among the key stakeholders in the industry, | | | | - Identify the key R&D challenges in the industry |
| particularly the pharmaceutical companies. While the | | | | and its impact on your company's R&D |
| R&D expenditure of the industry has steadily | | | | productivity. |
| increased, the output has been declining. The increase | | | | - Understand the three different focus areas of |
| in the number of late-stage development failures is | | | | improving R&D efficiency and select the one |
| costing the pharmaceutical industry dearly. In addition, | | | | best suited to the company's long term business |
| the stringent regulatory mechanisms on the pricing | | | | strategy. |
| and reimbursement of approved drugs have added | | | | - Develop more efficient and effective solutions by |
| to the pressure. Pharmaceutical companies have tried | | | | identifying the implementation issues from the case |
| many ways to improve the R&D efficiency | | | | studies and examples covered for each solution. |
| which include the acquisitions of small biotechnology | | | | - Ensure sustainable R&D growth by identifying |
| and pharmaceutical companies, R&D | | | | long term potential solutions to improve R&D |
| restructuring, outsourcing and better lifecycle | | | | efficiency. |
| management of their existing drugs in the market. | | | | - Create an integrated and agile R&D |
| However, there has been limited success achieved to | | | | organization through the understanding of key |
| date. | | | | technologies and other external partners in improving |
| This report is built using data and information sourced | | | | the R&D efficiency in future. |
| from proprietary databases, primary and secondary | | | | - Optimize R&D efforts by identifying the key |
| research and in house analysis by GBI Research's | | | | areas with maximum revenue potential in future. |
| team of industry experts. | | | | |